Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.

ABSTRACT: Progress in the treatment of adult high-grade gliomas (HGG), including chemoradiation with concurrent and adjuvant temozolomide for glioblastoma, has not translated into significant therapeutic advances for pediatric HGG, where overall survival has plateaued at 15% to 20%, especially when considering specialized pediatric treatment in tertiary care centers, maximal safe neurosurgical resection, optimized delivery of involved field radiation, and improvements in supportive care. However, recent advances in our understanding of pediatric HGG, including the application of next-generation sequencing and DNA methylation profiling, have identified mutations in the histone variant H3.3 and canonical H3.1 genes, respectively. These mutations are relatively specific to neuroanatomic compartments (c

SUBMITTER: Vanan MI 

PROVIDER: S-EPMC5398987 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature